Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
about
Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models.Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art.Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics.Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection.Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic virusesProtection against respiratory syncytial virus by a recombinant Newcastle disease virus vectorCyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesGenetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.Oncolysis by paramyxoviruses: preclinical and clinical studies.Fighting cancer with oncolytic viruses.Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.Oncolytic viruses: do they have a role in anti-cancer therapy?Oncolytic viruses & their specific targeting to tumour cells.Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and HostNovel oncolytic viral therapies in patients with thoracic malignancies.Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.ODE models for oncolytic virus dynamics.Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.Expression of transgenes from newcastle disease virus with a segmented genome.Use of oncolytic viruses for the eradication of drug-resistant cancer cells.Review: Oncolytic virotherapy, updates and future directions.Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton ratsFusogenic Viruses in Oncolytic Immunotherapy
P2860
Q25257260-51A628B6-248D-40C9-8582-916D907B54B2Q26827216-D6089656-43B9-4DF6-A447-DD8B8FF7F364Q33259239-DE02E850-0510-4EA1-9262-8EE37F5C0758Q33404103-66C45F4F-AEFC-47E3-92F9-BDBE2E91E8C4Q33773376-5BA71813-F2F7-4732-9461-8E3BB329A28CQ34302198-CB031702-7F7D-4F4A-BE55-2841656EF8E5Q35036505-735AC2B6-FC67-4939-AC14-38B35E1F3B62Q35699080-2CC0E461-497F-460B-81FD-3C835BE34C57Q35834369-0B4F9C4C-A1E0-4BD5-A68C-A74CD80F5690Q35861933-7E25FC7D-6C86-44E2-8C52-33EF3905A5D8Q36373017-D126AF17-5F75-42C6-BDCB-C13EEE8672CCQ37069810-C0C1AF76-B138-4F30-8AA0-8E614A59CBB5Q37133496-98A134ED-AD78-42E7-A2BF-B3BBCD398F3BQ37926486-4A5BD434-64FB-47F2-A40F-EE7EDB82ACD2Q38061306-5FCBD9A1-D14B-4E2E-8414-57B89B83ECFFQ38369289-D3D9015A-7519-4CB1-A1E1-EEC2629ADD1AQ39067827-4E704DDF-E9C4-47D3-9925-D7C2750A1F4CQ39322307-B246E99C-9D97-45B7-B7A3-5D1B2F6B08D7Q39634544-681FF44C-DCBB-428A-B3EF-3C34FADAC8CCQ39741135-A492EE70-4758-4247-92C9-E476FBC968D0Q41919169-56C1226F-9C53-4D3A-A1F0-5BACAD87DD32Q43159083-73178C7E-34BD-433D-A226-091C35E0B548Q47160989-5156354D-1387-4F8C-B78E-391EB8C4F970Q53739132-2BC0D98D-84C8-48E1-A07B-8F023571B9A1Q54967512-9FC2AF77-8A8B-4E8A-A67A-06F29F6FA903Q56794662-62E42DE3-37C7-4622-A1EC-B18327950616Q56971929-A294A957-813D-49E8-8437-276EFA142077
P2860
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@ast
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@en
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@nl
type
label
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@ast
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@en
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@nl
prefLabel
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@ast
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@en
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
@nl
P2093
P1476
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus
@en
P2093
Andrew L Pecora
M Scot Roberts
Michael K Bamat
Pierre P Major
Robert M Lorence
Scott A Laurie
Sebastien J Hotte
William S Groene
P304
P577
2003-12-01T00:00:00Z